非肝硬化性门静脉高压症的临床管理现状

徐京杭; 于岩岩; 徐小元

doi:10.3969/j.issn.1001-5256.2022.07.001

非肝硬化性门静脉高压症的临床管理现状

DOI: 10.3969/j.issn.1001-5256.2022.07.001

北京大学第一医院感染疾病科，北京 100034

基金项目:

国家科技重大专项 (2017ZX10202202)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：徐京杭负责收集资料并撰写文章；于岩岩、徐小元负责最终审阅定稿。

详细信息

通信作者:
徐小元，xiaoyuanxu6@163.com

计量
- 文章访问数: 817
- HTML全文浏览量: 176
- PDF下载量: 231
- 被引次数: 0
出版历程
- 收稿日期: 2022-05-15
- 录用日期: 2022-06-16
- 出版日期: 2022-07-20

Current status of the clinical management of non-cirrhotic portal hypertension

Department of Infectious Diseases, Peking University First Hospital, Beijing 100034, China

Research funding:

National Science and Technology Major Project (2017ZX10202202)

More Information

Corresponding author: XU Xiaoyuan, xiaoyuanxu6@163.com(ORCID: 0000-0002-1759-4330)

摘要

摘要: 非肝硬化性门静脉高压症并非罕见，其临床管理策略有别于肝硬化性门静脉高压症。按照发病机制和病因的不同，可分为肝前性、肝性和肝后性门静脉高压症，其中肝性可进一步分为窦前性、窦性和窦后性。结合临床表现、影像学与病理学检查及时诊断，并启动相应治疗是临床管理的关键。然而本组疾病异质性强，不易诊断，亟需临床工作者提高对本组疾病的认识，以期提高临床管理水平。
- 非肝硬化性门静脉高压 /
- 诊断 /
- 治疗学
Abstract: Non-cirrhotic portal hypertension (NCPH) is not uncommon, and its clinical management strategies are different from those for cirrhotic portal hypertension. According to pathogenesis and etiology, NCPH can be classified into prehepatic, hepatic, and posthepatic NCPH, among which hepatic NCPH can be further classified into presinusoidal, sinusoidal, and postsinusoidal NCPH. Timely diagnosis based on clinical manifestation, radiological examination, and pathology and initiation of corresponding treatment are the key to the clinical management of NCPH. However, the diseases in this group are highly heterogeneous and difficult to diagnose, and it is urgent for clinicians to improve their understanding of such diseases, so as to improve the level of clinical management.
- Noncirrhotic Portal Hypertension /
- Diagnosis /
- Therapeutics

HTML全文

参考文献(16)

[1]	HE FL, MA L, LI YR, et al. Non-cirrhotic portal hypertension: the highlight of its diagnosis[J]. J Prac Hepatol, 2022, 25(1): 1-4. DOI: 10.3969/j.issn.1672-5069.2022.01.001. 何福亮, 马琳, 李悦榕, 等. 非肝硬化性门脉高压的临床诊断[J]. 实用肝脏病杂志, 2022, 25(1): 1-4. DOI: 10.3969/j.issn.1672-5069.2022.01.001.
[2]	LASAGNI A, CADAMURO M, MORANA G, et al. Fibrocystic liver disease: novel concepts and translational perspectives[J]. Transl Gastroenterol Hepatol, 2021, 6: 26. DOI: 10.21037/tgh-2020-04.
[3]	WU X, ZHOU C, LUO SQ. Congenital hepatic fibrosis: clinical features of different clinical types in 75 patients[J]. Chin Hepatol, 2014, 19(7): 479-482, 490. https://www.cnki.com.cn/Article/CJFDTOTAL-ZUAN201407002.htm 吴欣, 周超, 罗生强. 先天性肝纤维化不同分型的临床特征——75例分析[J]. 肝脏, 2014, 19(7): 479-482, 490. https://www.cnki.com.cn/Article/CJFDTOTAL-ZUAN201407002.htm
[4]	HULTCRANTZ M, BJÖRKHOLM M, DICKMAN PW, et al. Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study[J]. Ann Intern Med, 2018, 168(5): 317-325. DOI: 10.7326/M17-0028.
[5]	GAVRIILIDIS P, MARANGONI G, AHMAD J, et al. State of the art, current perspectives, and controversies of Budd-Chiari syndrome: a review[J]. J Clin Med Res, 2022, 14(4): 147-157. DOI: 10.14740/jocmr4724.
[6]	de GOTTARDI A, RAUTOU PE, SCHOUTEN J, et al. Porto-sinusoidal vascular disease: proposal and description of a novel entity[J]. Lancet Gastroenterol Hepatol, 2019, 4(5): 399-411. DOI: 10.1016/S2468-1253(19)30047-0.
[7]	de FRANCHIS R, BOSCH J, GARCIA-TSAO G, et al. Baveno Ⅶ - Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76(4): 959-974. DOI: 10.1016/j.jhep.2021.12.022.
[8]	KRISHNA YR, YACHHA SK, SRIVASTAVA A, et al. Quality of life in children managed for extrahepatic portal venous obstruction[J]. J Pediatr Gastroenterol Nutr, 2010, 50(5): 531-536. DOI: 10.1097/MPG.0b013e3181b6a55d.
[9]	KHANNA R, SARIN SK. Idiopathic portal hypertension and extrahepatic portal venous obstruction[J]. Hepatol Int, 2018, 12(Suppl 1): 148-167. DOI: 10.1007/s12072-018-9844-3.
[10]	AKHAN O, KARAOSMANOGˇLU AD, ERGEN B. Imaging findings in congenital hepatic fibrosis[J]. Eur J Radiol, 2007, 61(1): 18-24. DOI: 10.1016/j.ejrad.2006.11.007.
[11]	CANNELLA R, GIAMBELLUCA D, DIAMARCO M, et al. Congenital cystic lesions of the bile ducts: imaging-based diagnosis[J]. Curr Probl Diagn Radiol, 2020, 49(4): 285-293. DOI: 10.1067/j.cpradiol.2019.04.005.
[12]	KMEID M, LIU X, BALLENTINE S, et al. Idiopathic non-cirrhotic portal hypertension and porto-sinusoidal vascular disease: review of current data[J]. Gastroenterology Res, 2021, 14(2): 49-65. DOI: 10.14740/gr1376.
[13]	ZHAO XY, ZHANG X, WANG TL, et al. Clinical and pathological features of patients with congenital hepatic fibrosis[J]. J Clin Heptaol, 2010, 26(2): 191-193. DOI: 10.3969/j.issn.1001-5256.2010.02.025. 赵新颜, 张新, 王泰龄, 等. 先天性肝纤维化14例临床病理特点[J]. 临床肝胆病杂志, 2010, 26(2): 191-193. DOI: 10.3969/j.issn.1001-5256.2010.02.025.
[14]	Cooperative Group for Hepatic and Gall Diseases, Chinese Society of Gastroenterology, Chinese Medical Association. Expert consensus on diagnosis and treatment of pyrrolidine alkaloids-related sinusoidal obstruction syndrome (2017, Nanjing)[J]. J Clin Hepatol, 2017, 33(9): 1627-1637. DOI: 10.3969/j.issn.1001-5256.2017.09.003. 中华医学会消化病学分会肝胆疾病协作组. 吡咯生物碱相关肝窦阻塞综合征诊断和治疗专家共识意见(2017年, 南京)[J]. 临床肝胆病杂志, 2017, 33(9): 1627-1637. DOI: 10.3969/j.issn.1001-5256.2017.09.003.
[15]	CORBACIOGLU S, TOPALOGLU O, AGGARWAL S. A systematic review and meta-analysis of studies of defibrotide prophylaxis for veno-occlusive disease/sinusoidal obstruction syndrome[J]. Clin Drug Investig, 2022. DOI: 10.1007/s40261-022-01140-y.[Onlineaheadofprint]
[16]	Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006. 中华医学会肝病学分会. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.